

TABLE 82: INCLUDED STUDY CHARACTERISTICS — POST-LIVER TRANSPLANT RECIPIENTS (N = 2)

INCLUDED STUDIES	TOTAL N	POPULATION (NAIVE, EXPERIENCED)	POPULATION AGE	TREATMENTS	COUNTRIES	RANDOMIZED (Y/N)
Not included in the NMA for all SVR						
Charlton et al., 2015	40	Combined	≥ 18 years All genotypes	SOF24 + RBV24	USA, Europe, New Zealand	No
Kwo et al., 2014 CORAL-I	34	Combined	18 to 70 years Genotype 1 No evidence of cirrhosis (METAVIR score ≤ F2)	PAR/RIT24 + OMB24 + DAS24 + RBV24	USA, Spain	No

DAS = dasabuvir; NMA = network meta-analysis; OMB = ombitasvir; PAR = paritaprevir; RBV = ribavirin; RIT = ritonavir; SOF = sofosbuvir.
 Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.